iOmx doses first patient in pivotal phase 1 study
Study becomes the first-in-human clinical trial involving OMX-0407 in a specific patient group - News - PharmaTimes
Source: pharmatimes.com
Murray Yule News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Murray Yule. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Murray Yule Today - Breaking & Trending Today
Chutes & Ladders—Pfizer poaches Roche's early R&D leader Pao to replace development chief
Pfizer picks from Roche's executive team, snagging pharma early R&D leader William Pao as the Big Pharma's next chief development officer. Leo Pharma poaches from ... a Danish meme stock for its new CEO, who will lead a reorganization of the dermatology biopharma. And Sio Gene Therapies CEO Cheruvu is out the door as Parkinson's program also hits the exit.
Source: fiercebiotech.com
iOmx Therapeutics Appoints Dr. Murray Yule as CMO to Lead Clinical Development
03.02.2022 iOmx Therapeutics Appoints Dr. Murray Yule as CMO to Lead Clinical Development | Chief Medical Officer | Dr. Murray Yule
Source: dgap.de
Adcendo Raises EUR 51M in Series A Financing
Adcendo, a Copenhagen, Denmark-based biotech company which is developing antibody-drug conjugates (ADCs) for the treatment of cancers, raised EUR 51m (US$ 62m) in Series A financing. The round was led by Novo Seeds and Ysios Capital, with participation from RA Capital Management, HealthCap and Gilde Healthcare. As part of the financing, Jeroen Bakker, Principal at Novo Seeds, will join the Board. The company plans to use the funds to bring the lead program targeting the novel cancer target uPARAP/Endo180 to proof of concept in patients. Founded in 2017 by scientists Niels Behrendt, Lars Henni...
Source: finsmes.com
Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers
Share this article Share this article COPENHAGEN, Denmark, April 29, 2021 /PRNewswire/ -- Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The investment was led by Novo Seeds, the early-stage investment and company creation team of Novo Holdings, and Ysios Capital, along with RA Capital Management, HealthCap and Gilde Healthcare. The company was initially incubated and funded at the BioInnovation Institute (BII). The new financing, which is th...
Source: prnewswire.com